Lead Sponsor

UNION therapeutics

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Capable of giving signed informed consent.
•2. Male and female patients ≥18 years of age
•3. Body weight of \>40 kg
•4. Diagnosis of chronic, stable plaque-type psoriasis. If the patient is diagnosed with psoriasis arthritis, the arthritis should be stable.
•5. Moderate-to-severe plaque-type psoriasis as defined by Psoriasis Activity and Severity Index (PASI) ≥12, body surface area (BSA) ≥10%, and Investigator Global Assessment (IGA) ≥3.
•6. Candidate for systemic antipsoriatic treatment or phototherapy.

•1. Therapy-resistant psoriasis
•2. Unstable psoriasis or psoriatic arthritis with acute deterioration within 4 weeks of the Screening visit.
•3. History of allergy or hypersensitivity to any component of the study treatment.
•4. Active infection (eg, bacteria, viral, fungal) requiring treatment with systemic antibiotics within 4 weeks of the Screening visit.
•5. Malignancy or history of malignancy except for treated (ie, cured) basal cell skin carcinomas.